Get the right depression/anxiety medicine the first time. Molecular diagnostics company specializing in the field of pharmacogenomics (PGx).
Total raised: $69M
Investors 2
| Date | Name | Website |
| - | Biobrit | biobrit.co... |
| - | Telegraph ... | thpartners... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 25.04.2017 | Series D | $27M | - |
| 14.12.2015 | Series C | $30M | - |
| 13.04.2010 | - | $6M | - |
| 21.08.2009 | - | $6M | - |
Mentions in press and media 20
| Date | Title | Description |
| 18.06.2025 | Why Claims Data Alone Leave Gaps in Understanding the Patient Journey | Noah Nasser, CEO at datma In today’s precision medicine landscape, pharmaceutical companies and access teams face a critical challenge: understanding not just whether therapies work, but how they are accessed, adopted, and experienced by re... |
| 18.08.2021 | AltheaDx, Inc. expands its leadership team to address the need for precision medicine in Mental Health; appoints healthcare veterans Jonathan Yount as SVP of Sales and Croom Lawrence as SVP Marketing. | |
| 07.06.2021 | AltheaDx, Inc. launches webinar series on Mental Health; Precision Diagnostics for depression and anxiety | |
| 22.06.2019 | Pioneering genetic-testing company Myriad's biggest up-and-coming product could be at risk after scientists raised major questions | Advertisement Genetic tests like one offered by Myriad Genetics claim to analyze a patient's DNA and point them to the best depression drug for them. Myriad's test is called GeneSight and costs $2,000. It's covered for seniors on the govern... |
| 26.04.2017 | AltheaDx Finds $27M In New Funding | San Diego-based AltheaDx, which is developing molecular diagnostics technology for the personalized medicine market, has raised $27M in its Series D funding round. Source of the new funding was not announced by the company. AltheaDx said th... |
| 26.04.2017 | AltheaDx Closes $27M Series D | SAN DIEGO, CA, Commercial stage molecular diagnostics company specializing in the field of personalized medicine, today announced that it has raised $27 million in its Series D funding. >> Click here for more funding data on Althea... |
| 26.04.2017 | Term Sheet — Wednesday, April 26 | ET CETERA Good morning! This the third-largest ever “ed tech” deal, aside from German publishing giant Bertelsmann’s $230 million stake in HotChalk and a $200 million fundraising by TutorGroup, an Alibaba-backed English tutoring startup. Th... |
| 26.04.2017 | Precision Medicine Startup AltheaDx Lands $27M to Expand Personalized Therapeutic Decisions Internationally | AltheaDx, Inc., a San Diego, CA-based commercial stage molecular diagnostics company specializing in the field of personalized medicine has raised $27 million in Series D funding. The company is a CAP-accredited, CLIA-certified laboratory a... |
| 25.04.2017 | AltheaDx Closes $27M Series D Funding | AltheaDx, Inc., a San Diego, CA-based commercial stage molecular diagnostics company specializing in the field of personalized medicine, raised $27m in Series D funding. The backers were not disclosed. The company intends to use the funds t... |
| 14.12.2015 | AltheaDx Completes $30M Series C Financing | SAN DIEGO, CA, Leading personalized medicine company, today announced it has raised $30 million in Series C financing. >> Click here for more funding data on AltheaDx >> To export AltheaDx funding data to PDF and Excel, clic... |
Show more